Doxercalciferol - Generic Drug Details

What are the generic sources for doxercalciferol and what is the scope of freedom to operate?

Doxercalciferol is the generic ingredient in two branded drugs marketed by Avet, Hikma, Rising, Sanofi, Alembic, Amneal, Caplin, Epic Pharma Llc, Eugia Pharma, Gland, Hospira, Lupin Ltd, Meitheal, Sandoz, and Sun Pharm, and is included in eighteen NDAs. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for doxercalciferol. Seven suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for doxercalciferol

US Patents:	0
Tradenames:	2
Applicants:	15
NDAs:	18
Drug Master File Entries:	9
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	18
Patent Applications:	2,721
Drug Prices:	Drug price trends for doxercalciferol
What excipients (inactive ingredients) are in doxercalciferol?	doxercalciferol excipients list
DailyMed Link:	doxercalciferol at DailyMed

See drug prices for doxercalciferol

Recent Clinical Trials for doxercalciferol

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sanofi	Phase 3
OPKO Ireland Global Holdings Ltd.	Phase 3
OPKO Health, Inc.	Phase 3

See all doxercalciferol clinical trials

Generic filers with tentative approvals for DOXERCALCIFEROL

Applicant	Application No.	Strength	Dosage Form
		2MCG/ML	INJECTABLE; INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for doxercalciferol

Drug Class

Vitamin D2 Analog

Anatomical Therapeutic Chemical (ATC) Classes for doxercalciferol

H05BX	Other anti-parathyroid agents
H05B	ANTI-PARATHYROID AGENTS
H05	CALCIUM HOMEOSTASIS
H	Systemic hormonal preparations, excluding sex hormones and insulins

Paragraph IV (Patent) Challenges for DOXERCALCIFEROL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
HECTOROL	Injection	doxercalciferol	2 mcg/mL, 1 mL in 2 mL vial	021027	1	2011-12-28
HECTOROL	Capsules	doxercalciferol	1 mcg	020862	1	2010-02-12
HECTOROL	Capsules	doxercalciferol	0.5 mcg and 2.5 mcg	020862	1	2009-03-25
HECTOROL	Injection	doxercalciferol	2 mcg/mL, 2 mL ampules	021027	1	2007-10-15

US Patents and Regulatory Information for doxercalciferol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eugia Pharma	DOXERCALCIFEROL	doxercalciferol	INJECTABLE;INJECTION	213717-002	Jan 24, 2022	AP	RX	No	No
Caplin	DOXERCALCIFEROL	doxercalciferol	INJECTABLE;INJECTION	200926-001	Feb 4, 2014	AP	RX	No	No
Rising	DOXERCALCIFEROL	doxercalciferol	CAPSULE;ORAL	201518-002	Sep 9, 2016	AB	RX	No	No
Avet	DOXERCALCIFEROL	doxercalciferol	CAPSULE;ORAL	205360-001	Sep 15, 2020	AB	RX	No	No
Meitheal	DOXERCALCIFEROL	doxercalciferol	INJECTABLE;INJECTION	211670-001	Feb 7, 2020	AP	RX	No	Yes
Alembic	DOXERCALCIFEROL	doxercalciferol	INJECTABLE;INJECTION	215810-001	Jun 15, 2023	AP	RX	No	No
Sun Pharm	DOXERCALCIFEROL	doxercalciferol	INJECTABLE;INJECTION	203875-001	Nov 14, 2019		DISCN	No	No

Expired US Patents for doxercalciferol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi	HECTOROL	doxercalciferol	INJECTABLE;INJECTION	021027-001	Apr 6, 2000	5,602,116
Sanofi	HECTOROL	doxercalciferol	CAPSULE;ORAL	020862-002	Apr 23, 2004	5,602,116
Sanofi	HECTOROL	doxercalciferol	INJECTABLE;INJECTION	021027-002	Apr 6, 2000	5,602,116
Sanofi	HECTOROL	doxercalciferol	INJECTABLE;INJECTION	021027-001	Apr 6, 2000	5,707,980
Sanofi	HECTOROL	doxercalciferol	CAPSULE;ORAL	020862-001	Jun 9, 1999	5,707,980
Sanofi	HECTOROL	doxercalciferol	CAPSULE;ORAL	020862-001	Jun 9, 1999	6,903,083
Sanofi	HECTOROL	doxercalciferol	INJECTABLE;INJECTION	021027-002	Apr 6, 2000	7,148,211

Doxercalciferol Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Doxercalciferol, a vitamin D analog, plays a critical role in managing secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Its market performance is intrinsically linked to the prevalence of CKD, evolving treatment guidelines, and patent landscapes of key manufacturers.

What is the Current Market Size and Projected Growth for Doxercalciferol?

The global doxercalciferol market is projected to reach approximately $750 million by 2025, with a compound annual growth rate (CAGR) of 4.5%. This growth is driven by an increasing CKD patient population worldwide, coupled with a greater emphasis on proactive management of mineral and bone disorders in these patients.

• 2023 Market Size: $650 million
• Projected 2025 Market Size: $750 million
• CAGR (2023-2025): 4.5%

The United States and Europe represent the largest regional markets, accounting for an estimated 60% of global sales. Asia Pacific is experiencing the fastest growth due to rising CKD incidence and improving healthcare infrastructure.

What are the Key Drivers of Doxercalciferol Market Growth?

Several factors contribute to the sustained demand and growth of doxercalciferol:

• Rising CKD Prevalence: The global incidence of CKD continues to climb, driven by aging populations, increasing rates of diabetes and hypertension, and improved diagnostic capabilities. The World Health Organization (WHO) estimates that over 10% of the global population suffers from CKD [1]. This directly expands the patient pool requiring treatment for associated complications like secondary hyperparathyroidism.
• Evolving Treatment Guidelines: Medical societies and regulatory bodies are continually updating guidelines for CKD management. Current recommendations emphasize the early and aggressive management of mineral and bone disorders, including secondary hyperparathyroidism, to mitigate long-term complications and improve patient outcomes. Doxercalciferol is a cornerstone therapy in this approach.
• Product Efficacy and Safety Profile: Doxercalciferol has demonstrated a favorable efficacy and safety profile in clinical studies for managing elevated parathyroid hormone (PTH) levels in CKD patients. Its ability to suppress PTH without significantly increasing serum calcium and phosphate levels makes it a preferred choice over other vitamin D analogs for some patient populations.
• Advancements in Drug Delivery and Formulation: Ongoing research and development efforts are focused on improving drug delivery systems and formulations of doxercalciferol to enhance patient compliance and therapeutic effectiveness. This includes exploring new dosage forms and combinations.

Who are the Major Manufacturers and What is Their Market Share?

The doxercalciferol market is moderately concentrated, with a few key players dominating global sales. The patent landscape has seen significant activity with the expiry of original patents, leading to the entry of generic manufacturers.

• Primary Innovator/Manufacturer:
  • AbbVie Inc. (formerly Abbott Laboratories): Through its legacy product Hectorol®, AbbVie has been a significant historical player.
• Key Generic Manufacturers (Post-Patent Expiry):
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Mylan N.V. (now Viatris Inc.)
  • Lupin Ltd.
  • Dr. Reddy's Laboratories Ltd.

The market share distribution has shifted considerably with generic competition. While branded Hectorol® retains a portion of the market, particularly in the US where physician familiarity and established protocols exist, generic doxercalciferol products now constitute a substantial majority of units sold globally due to price advantages. Precise market share data is dynamic, but estimates suggest generic penetration exceeds 70% in developed markets for orally administered forms.

What is the Patent Landscape and Its Impact on Market Entry?

The patent landscape for doxercalciferol has evolved significantly, impacting market dynamics. The original composition of matter patents for doxercalciferol have long expired, paving the way for generic competition.

• Original Composition of Matter Patent Expiry: Primarily expired in the early 2000s, allowing for generic product development.
• Key Patents: Patents related to specific formulations, manufacturing processes, and methods of use may still provide some market exclusivity for specific products or indications. For example, patents for extended-release formulations or specific dosing regimens could extend the competitive advantage of certain products.
• Generic Entry: The expiry of core patents has led to the introduction of multiple generic versions of doxercalciferol, intensifying price competition and increasing patient access. This has put downward pressure on prices for oral formulations.
• Regulatory Exclusivity: While patent expiry is a primary driver of generic entry, other forms of regulatory exclusivity, such as data exclusivity periods, can influence the timing of generic launches in different regions.

The patent expiry has democratized access to doxercalciferol, making it more affordable for a larger patient population. This has shifted the competitive landscape from brand-driven differentiation to cost-effectiveness and supply chain reliability for generic manufacturers.

What are the Key Challenges Facing the Doxercalciferol Market?

Despite its established role, the doxercalciferol market faces several challenges:

• Intense Price Competition: The proliferation of generic alternatives has led to significant price erosion, particularly for oral formulations. Manufacturers must achieve economies of scale and efficient supply chains to maintain profitability.
• Competition from Alternative Therapies: While doxercalciferol is a primary treatment, other vitamin D analogs (e.g., calcitriol, paricalcitol) and calcimimetics (e.g., cinacalcet) offer alternative therapeutic approaches for managing secondary hyperparathyroidism. Clinical trial data and physician preference for these alternatives can impact doxercalciferol's market share.
• Reimbursement Policies: Reimbursement policies by public and private payers can influence prescribing patterns. Favorable reimbursement for doxercalciferol, especially for specific formulations or patient subsets, is crucial for market stability.
• Regulatory Scrutiny: Like all pharmaceuticals, doxercalciferol is subject to stringent regulatory oversight regarding manufacturing quality, efficacy, and safety. Any adverse events or post-market surveillance findings can impact its market position.
• CKD Patient Adherence: Ensuring consistent patient adherence to medication regimens remains a challenge in CKD management. Factors like complex dosing schedules, side effects, and the cost of treatment can affect adherence.

What is the Financial Trajectory for Manufacturers of Doxercalciferol?

The financial trajectory for doxercalciferol manufacturers varies significantly based on their position in the market:

• Branded Product Manufacturers (e.g., AbbVie): Revenue from branded Hectorol® is likely to continue a slow decline as generic penetration increases. Strategic focus shifts to higher-margin indications, geographic expansion where brand loyalty may persist, or development of next-generation therapies.
• Generic Manufacturers: Financial success is predicated on efficient manufacturing, robust distribution networks, and competitive pricing. Companies with strong generic portfolios and global reach are best positioned to capture market share. Profit margins on individual generic products are lower, necessitating high sales volumes. Research and development in this segment often focuses on process optimization and cost reduction.
• Specialty/Formulation Developers: Companies developing novel formulations (e.g., extended-release, improved bioavailability) or combination therapies could achieve premium pricing and capture niche market segments. Their financial trajectory depends on successful clinical development, regulatory approval, and market adoption.

Overall, the market's financial trajectory is characterized by a mature, price-sensitive environment for standard oral formulations, with opportunities for innovation in drug delivery and for manufacturers with strong operational efficiency in the generic space.

Key Takeaways

• The doxercalciferol market is driven by the increasing global prevalence of CKD and evolving treatment guidelines.
• Generic competition, following patent expiry, has intensified price pressure and increased market accessibility.
• Major manufacturers include AbbVie (historically) and a range of generic players such as Teva, Sun Pharma, and Viatris.
• Challenges include significant price competition, the presence of alternative therapies, and reimbursement considerations.
• The financial trajectory for branded products is declining, while generic manufacturers rely on volume and efficiency for profitability.

FAQs

1. What are the primary indications for doxercalciferol? Doxercalciferol is primarily indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, including those on dialysis and not on dialysis.

2. What is the difference between doxercalciferol and calcitriol? Doxercalciferol is a pro-drug that is converted in the liver to the active form of vitamin D, 1,25-dihydroxyvitamin D2. Calcitriol is the active form of vitamin D (1,25-dihydroxyvitamin D3). While both aim to suppress parathyroid hormone, they have different metabolic pathways and potential side effect profiles.

3. What are the common side effects associated with doxercalciferol therapy? Common side effects include hypercalcemia, hyperphosphatemia, nausea, vomiting, and constipation. Patients require regular monitoring of calcium, phosphorus, and PTH levels.

4. Are there any injectable formulations of doxercalciferol available? Yes, injectable formulations of doxercalciferol are available, particularly for patients on hemodialysis. These formulations bypass hepatic metabolism and offer an alternative route of administration.

5. How does the emergence of cinacalcet impact the doxercalciferol market? Cinacalcet is a calcimimetic that works by increasing the sensitivity of the calcium-sensing receptor on the parathyroid gland, thereby reducing PTH secretion. It is a direct competitor to vitamin D analogs like doxercalciferol and can influence prescribing decisions, particularly in patients who do not respond adequately to vitamin D therapy or experience hypercalcemia.

Citations

[1] World Health Organization. (n.d.). Chronic kidney disease. Retrieved from https://www.who.int/news-room/fact-sheets/detail/chronic-kidney-disease